Skip to main content
INAB
NASDAQ Life Sciences

IN8BIO Amends Shelf Registration for Potential $200M Capital Raise Amid Going Concern Warning

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.42
Mkt Cap
$13.983M
52W Low
$1.17
52W High
$5.61
52W Position info
21% above low
Off High info
75% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

INAB sits 21% above its 52-week low of $1.17.

Summary

IN8BIO filed an amended shelf registration statement, allowing it to offer and sell up to $200 million in various securities, a critical move for the company facing a 'going concern' warning and limited cash runway.


Key Events · Financing and Capital Events · INAB

  • Amended Shelf Registration Filed

    IN8BIO filed an Amendment No. 1 to its Form S-3 registration statement, initially filed on November 7, 2025, to update information and include an updated auditor consent.

  • Potential $200 Million Capital Raise

    The filing registers the ability to offer and sell up to an aggregate of $200,000,000 of common stock, preferred stock, debt securities, warrants, rights, or units from time to time.

  • Extreme Potential Dilution

    The potential $200 million capital raise is over 14 times the company's current market capitalization of approximately $14 million, indicating a massive potential for dilution for existing shareholders.

  • Addresses Going Concern Warning

    This financing mechanism is critical for the company, which recently reported a 'going concern' warning and a cash runway extending only through April 2027, necessitating significant capital to continue operations and R&D programs.


Analysis · INAB · Life Sciences

This amended shelf registration allows IN8BIO to potentially raise up to $200 million through various securities. Given the company's current market capitalization of approximately $14 million and its recent disclosure of a 'going concern' warning with a cash runway only through April 2027, this represents an extremely high potential for dilution for existing shareholders. While necessary for the company's survival and to fund operations and R&D, the magnitude of the potential capital raise relative to its current valuation indicates a severe impact on per-share value.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INAB was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14M. The 52-week trading range was $1.17 to $5.61. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INAB - Latest Insights

INAB
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.820
Real-time Price: $0.750 info
Change: -$0.070 (-9%) info
Market Cap: $8.193M info
INAB
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.840
Real-time Price: $0.750 info
Change: -$0.090 (-11%) info
Market Cap: $8.193M info
INAB
Aug 06, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.9888
Real-time Price: $0.750 info
Change: -$0.2388 (-24%) info
Market Cap: $8.193M info
INAB
Jul 09, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $0.750 info
Change: -$0.640 (-46%) info
Market Cap: $8.193M info
INAB
Jun 01, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.93
Real-time Price: $0.750 info
Change: -$1.18 (-61%) info
Market Cap: $8.193M info